Literature DB >> 24816815

Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure.

B Wang1, B B Xiao, C G Shang, K Wang, R S Na, X X Nu, Q Liao.   

Abstract

Bacterial vaginosis frequently persists, even after treatment. The role of some strains of bacteria associated with bacterial vaginosis treatment failure remains poorly defined. The aim of our study was to define the risk of bacterial vaginosis treatment failure, including pre-treatment detection of specific vaginal bacteria. Bacterial vaginosis is present when the Nugent score is ≥7 and the modified Amsel criteria is positive. Women with bacterial vaginosis were treated with intravaginal metronidazole gel nightly for 5 nights. The 454 pyrosequencing method was used to detect bacteria in vaginal fluid. By univariate analysis, a history of bacterial vaginosis, intrauterine device use and the presence of Facklamia, Corynebacterium and Veillonella were significantly associated with bacterial vaginosis treatment failure. Lactobacillus crispatus, Lactobacillus pentosus and Megasphaera were significantly associated with curing bacterial vaginosis. After logistic regression analysis and detection of these bacteria for test-of-cure, we found that women who had a history of bacterial vaginosis had a higher incidence of bacterial vaginosis treatment failure, whereas women with L. crispatus had a lower incidence of treatment failure. Post-treatment sexual activity was not associated with the treatment effect. Our data suggested that treatment failure may be not caused by drug resistance. Rather, it has a closer relationship with the failed restoration of lactobacilli.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816815     DOI: 10.1007/s10096-014-2128-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  44 in total

1.  Identification of predominant culturable vaginal Lactobacillus species and associated bacteriophages from women with and without vaginal discharge syndrome in South Africa.

Authors:  Leonard H Damelin; Maria Paximadis; Demetra Mavri-Damelin; Monica Birkhead; David A Lewis; Caroline T Tiemessen
Journal:  J Med Microbiol       Date:  2010-10-28       Impact factor: 2.472

2.  Association of Mobiluncus curtisii with recurrence of bacterial vaginosis.

Authors:  Michelle C Meltzer; Renee A Desmond; Jane R Schwebke
Journal:  Sex Transm Dis       Date:  2008-06       Impact factor: 2.830

3.  Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial.

Authors:  Sixto Sanchez; Patricia J Garcia; Katherine K Thomas; Mary Catlin; King K Holmes
Journal:  Am J Obstet Gynecol       Date:  2004-12       Impact factor: 8.661

4.  Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.

Authors:  Jack D Sobel; Daron Ferris; Jane Schwebke; Paul Nyirjesy; Harold C Wiesenfeld; Jeffrey Peipert; David Soper; Suzanne E Ohmit; Sharon L Hillier
Journal:  Am J Obstet Gynecol       Date:  2006-04-21       Impact factor: 8.661

5.  A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.

Authors:  J R Schwebke; R A Desmond
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

6.  Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis.

Authors:  C H Livengood; D E Soper; K L Sheehan; D E Fenner; M G Martens; A L Nelson; M Ismail; J M Thorp; M Lappin; B J Long; T Blackwelder; R L Sweet; S Sagov
Journal:  Sex Transm Dis       Date:  1999-03       Impact factor: 2.830

7.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

8.  Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID.

Authors:  Jeanne M Marrazzo; David H Martin; D Heather Watts; Joann Schulte; Jack D Sobel; Sharon L Hillier; Carolyn Deal; David N Fredricks
Journal:  Sex Transm Dis       Date:  2010-12       Impact factor: 2.830

9.  Bacterial vaginosis, HIV serostatus and T-cell subset distribution in a cohort of East African commercial sex workers: retrospective analysis.

Authors:  John J Schellenberg; Catherine M Card; T Blake Ball; Jane Njeri Mungai; Erastus Irungu; Joshua Kimani; Walter Jaoko; Charles Wachihi; Keith R Fowke; Francis A Plummer
Journal:  AIDS       Date:  2012-01-28       Impact factor: 4.177

10.  Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group.

Authors:  S L Hillier; R P Nugent; D A Eschenbach; M A Krohn; R S Gibbs; D H Martin; M F Cotch; R Edelman; J G Pastorek; A V Rao
Journal:  N Engl J Med       Date:  1995-12-28       Impact factor: 91.245

View more
  10 in total

1.  Prognostic Indicators of Recurrence of Bacterial Vaginosis.

Authors:  Jack D Sobel; Navkiranjot Kaur; Nicole A Woznicki; Dina Boikov; Tina Aguin; Gurveer Gill; Robert A Akins
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

2.  Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis.

Authors:  Bryan T Mayer; Sujatha Srinivasan; Tina L Fiedler; Jeanne M Marrazzo; David N Fredricks; Joshua T Schiffer
Journal:  J Infect Dis       Date:  2015-02-12       Impact factor: 5.226

3.  Novel Selective Inhibition of Lactobacillus iners by Lactobacillus-Derived Bacteriocins.

Authors:  Trine Nilsen; Iwona Swedek; Laurel A Lagenaur; Thomas P Parks
Journal:  Appl Environ Microbiol       Date:  2020-10-01       Impact factor: 4.792

4.  Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis.

Authors:  Noelle Noyes; Kyu-Chul Cho; Jacques Ravel; Larry J Forney; Zaid Abdo
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

5.  Association between preterm delivery and bacterial vaginosis with or without treatment.

Authors:  Masao Shimaoka; Yoshie Yo; Kunihiko Doh; Yasushi Kotani; Ayako Suzuki; Isao Tsuji; Masaki Mandai; Noriomi Matsumura
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

6.  Abnormal vaginal microbiome associated with vaginal mesh complications.

Authors:  Nikolaus Veit-Rubin; Renaud De Tayrac; Rufus Cartwright; Larissa Franklin-Revill; Sophie Warembourg; Catherine Dunyach-Remy; Jean-Philippe Lavigne; Vik Khullar
Journal:  Neurourol Urodyn       Date:  2019-08-11       Impact factor: 2.696

7.  Quantitative modeling predicts mechanistic links between pre-treatment microbiome composition and metronidazole efficacy in bacterial vaginosis.

Authors:  Christina Y Lee; Ryan K Cheu; Melissa M Lemke; Andrew T Gustin; Michael T France; Benjamin Hampel; Andrea R Thurman; Gustavo F Doncel; Jacques Ravel; Nichole R Klatt; Kelly B Arnold
Journal:  Nat Commun       Date:  2020-12-01       Impact factor: 14.919

8.  Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes.

Authors:  Ashomathi Mollin; Mounika Katta; Jack D Sobel; Robert A Akins
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

9.  Veillonellaceae family members uniquely alter the cervical metabolic microenvironment in a human three-dimensional epithelial model.

Authors:  Mary E Salliss; Jason D Maarsingh; Camryn Garza; Paweł Łaniewski; Melissa M Herbst-Kralovetz
Journal:  NPJ Biofilms Microbiomes       Date:  2021-07-06       Impact factor: 7.290

10.  The vaginal microbiota in the course of bacterial vaginosis treatment.

Authors:  Romy D Zwittink; Ellen H A van den Munckhof; Maurine A Leverstein-van Hall; Kim Boers; Anco Molijn; Cornelis W Knetsch; Ed J Kuijper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-07       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.